Policy & Regulation
Tango Therapeutics Bolsters Management Team
15 May 2018 - - Cambridge, Massachusetts-based context-dependent cancer treatments developer Tango Therapeutics has expanded its management team with the promotion of Alan Huang, Ph.D. to chief scientific officer, and the addition of Charles Davis, Ph.D., as senior vice president, pharmaceutical sciences (DMPK, safety assessment and clinical pharmacology), the company said.
The new appointments expand on Tango's expertise in oncology translational research and clinical pharmacology as the company advances its goal of creating novel, targeted medicines for specific cancer subtypes using the principle of synthetic lethality.
Huang joined Tango Therapeutics as senior vice president, head of biology, after serving as a consultant at Third Rock Ventures, where he played a leading role in the creation and launch of Tango.
At Tango, he has led the process of designing and building Tango's novel, CRISPR-based, target discovery platform, and has been instrumental in advancing programs in drug discovery.
Before joining Third Rock, Huang worked at the Novartis Institutes for BioMedical Research as senior director and interim global head of oncology translational research. He began his career at Millennium Pharmaceuticals.
Huang earned his B.S. in biochemistry from Fudan University and his doctorate in biochemistry and molecular biology from the University of South Alabama.
Davis comes to Tango from the Novartis Institutes for BioMedical Research, where he served as vice president, PK sciences.
Before joining Novartis, Davis spent more than 20 years at GlaxoSmithKline. He has a B.A. in chemistry from Swarthmore College and a Ph.D. in biophysical chemistry from Cornell University.
Tango Therapeutics is a biotechnology company developing novel medicines for patients by discovering and drugging context-dependent vulnerabilities in cancers.


Related Headlines